Has Andro Giorgadze received payments from drug or device companies?

Yes. Drug and device makers reported $211 in general payments to Andro Giorgadze across 3 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Andro Giorgadze did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Andro Giorgadze come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Andro Giorgadze

Psychiatry · Smyrna, GANPI 1518001882

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 3 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Livanova USA, Inc. accounts for 80.8% of it on its own, with 2 other manufacturers making up the rest. 2025 is the largest year on record at $170, 9.0 times the $19 reported in 2019. That places this record below the midpoint for psychiatry clinicians in GA, where the typical reported total is $362.

$211in general payments, 2019–2025

Across 3 payments — averaging $70.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Livanova USA, Inc.$170
Alkermes, Inc.$21
Johnson & Johnson$19

$667,427in research payments, 2019–2025

Across 104 payments — averaging $6417.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

AbbVie$644K
Shire North American Group Inc$19K
Takeda Pharmaceuticals U.S.A., Inc.$5K

What the payments were for

Food & beverage$211100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Livanova USA, Inc.	1	$170
Alkermes, Inc.	1	$21
Johnson & Johnson	1	$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

VNS Therapy Symmetry Model 8103 Generator$170

How this compares

$211 in reported general payments places this provider in the 40th percentile of 900 psychiatry providers in Georgia.

See all psychiatry providers in Georgia →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Trazodone Hcl	11	$178
Duloxetine Hcl	18	$139
Gabapentin	14	$59
Clonazepam	11	$36
Zolpidem Tartrate	13	$28

Paid to pharmacies, not to this prescriber.

Other psychiatry in Smyrna

Munjal ShroffSmyrna$316K
Jeffrey KlopperSmyrna$18K
Richard PettyLoganville$2.9M
Ann GrooverCalhoun$1.4M
Todd AntinDecatur$1M
Michael BanovMarietta$733K
Ben HunterBrookhaven$499K
Joel MorganValdosta$337K
David PurselleAtlanta$307K
Jose CangianoAthens$244K

See the full list for Georgia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →